Epix Says FDA Will Take More Time to Review Vasovist Appeal
This article was originally published in The Pink Sheet Daily
Executive Summary
Company expects to hear a response to the appeal from agency in September.
You may also be interested in...
Vasovist Approval Strategy: Another Appeal, Not Another Trial
Epix believes data already submitted to FDA backs approval of imaging agent.
Vasovist Approval Strategy: Another Appeal, Not Another Trial
Epix believes data already submitted to FDA backs approval of imaging agent.
Epix Seeking New Partner For Blood Clot Imaging Agent EP-2104R
Phase IIb trials will not begin without a partner after Schering AG relinquishes option.